Pioneers and Innovators in #Psilocybin Treatments (OTCQB: $KAYS)
(NASDAQ: $CMPS) (NYSE: $CYBN) (OTC: $MSSTF) @COMPASSPathway @CybinInc
@MindsetPharma
How #BigPharma wants in on the Game
October 19, 2023 - Investorideas.com (https://www.investorideas.com) a global investor news source covering psilocybin and psychedelic health
and wellness stocks releases a special news report featuring Kaya Holdings,
Inc. (OTCQB:KAYS). As psilocybin
and other alternative health innovators try to shape the future of mental
health, Pharma and traditional healthcare investors are watching and waiting to
get their share.
Read this article, featuring KAYS in full at https://www.investorideas.com/news/2023/cannabis/10191Psilocybin-Treatments.asp
According to recent research published in
September, “In recent years, the potential therapeutic benefits of psychedelics
have been well documented, with research suggesting that these compounds can be
effective for treating a range of mental health disorders, from depression and
anxiety to addiction. Additionally, research has shown that psychedelics may be
effective in promoting personal growth and well-being. As a result, many
pharmaceutical companies and research institutions have increased their focus
on developing psychedelic-based treatments. It was observed that in 2021,
nearly USD 2 billion had been invested in the psychedelics sector in over 60
financing events during the past year.”
Seeing the growing opportunity, Kaya Holdings, Inc. (OTCQB:KAYS) is the only U.S. public company engaged in securing an Oregon Health Authority (“OHA”) license to open a psilocybin treatment center.
Kaya Holdings just announced that it has
closed an additional round of bridge financing targeted to complete KAYS'
planned psilocybin treatment center in Portland, Oregon. The facility will
operate under the name "The Sacred Mushroom™.
Total funds received from our bridge financing
since the first installment was received in June 2023, are $600,000, with no
commissions or fees associated with the financing. The funds are not
convertible into KAYS stock. $100K of the funds are in the form of short-term
financing with repayment due March 15, 2023, and $500K is due to be repaid from
10% of KAYS' revenues quarterly, with any unpaid balance due June 30, 2025.
Continued: We believe that
KAYS is presently the only U.S. public company engaged in securing an Oregon
Health Authority ("OHA") license to open a psilocybin treatment
center, aiming to create a setting that is unmatched by any other facility and
providing access to relief from treatment-resistant mental health conditions,
including depression, anxiety, additions, and eating disorders.
Continued: A recently
published report on psilocybin treatment prices in Oregon showed that Initial
prices for one facility range from $300 for a group microdose session to $3,500
for an individual high-dose session, with another facility pricing first-time
full-dose treatments at $15,000 (these prices do not include the cost of the
psilocybin, which can run from $300 to $500).
KAYS expects its planned model facility to offer a
superior setting, broader activity and treatment options, integrated
cultivation and processing, and accessible pricing, thereby enabling us to
deliver a superior treatment experience at a much lower price than the
competition, while still achieving profitability.
The Sacred Mushroom™ has approximately 11,000 sq
ft. and will provide visitors with access to our microdosing café, private
treatment rooms and group session areas, and activity zones with yoga, listening
stations, journaling chairs, and art expression for distinctive, effective, and
positive psilocybin treatments.
Continued: KAYS expects to
complete its initial license application within the next 30 days, and subject
to OHA approval, intends to bring the facility online within 90 days. KAYS
plans to operate The Sacred Mushroom™ as part of its Fifth Dimension
Therapeutics, Inc. subsidiary ("FDT"), which also plans to work
cooperatively with select pharmaceutical companies to maximize the curative potential
of psilocybin.
COMPASS Pathways plc (NASDAQ:CMPS) is pioneering
the development of a new model of psilocybin treatment, in which its
proprietary formulation of synthetic psilocybin, COMP360, is administered in
conjunction with psychological support. COMP360 has been designated a
Breakthrough Therapy by the US Food and Drug Administration (FDA) and has
received Innovative Licensing and Access Pathway (ILAP) designation in the UK
for treatment-resistant depression (TRD).
Evidencing that traditional healthcare investors
are now betting on psilocybin and psychedelic health and wellness, COMPASS announced in August a $285
Million Private Placement financing joined by leading healthcare Investors.
From the news: Kabir Nath, Chief
Executive Officer of COMPASS Pathways, said, “We are grateful for the support
of this group of leading healthcare investors for our work to bring potentially
transformative treatment for mental health conditions to patients urgently in
need of better options. We thank these investors for their confidence in our
rigorous approach to building a strong base of evidence for the potential of
COMP360 psilocybin treatment to help people with treatment-resistant depression
(TRD), post-traumatic stress disorder and anorexia nervosa. We expect that the
net proceeds will allow us to advance our pivotal phase 3 program in TRD and
achieve important milestones in the development of COMP360. We view this
investment as a validation of the potential of psychedelic medicine and the
importance of a rigorous and evidence-based approach.”
Cybin Inc. (NYSE: CYBN) is a
clinical-stage biopharmaceutical company on a mission to create safe and
effective psychedelic-based therapeutics to address the large unmet need for
new and innovative treatment options for people who suffer from mental health
conditions.
Breaking through into mainstream, Cybin recently presented an
abstract and moderated a Psychedelic Workshop at the 6th Annual
Neuropsychiatric Drug Development Summit.
From the news: Cybin
announced that its abstract describing a comprehensive structure-activity relationship
study of a series of novel serotonergic phenethylamines has been selected for
presentation at the Neuropsychiatric Drug Development Summit taking place
October 11-12 in Boston, MA.
The abstract, entitled "Structure-activity of
2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with
therapeutic potential," summarizes the studies, which identified multiple
potential compounds of therapeutic potential with attractive drug-like
characteristics, including good safety profile, high oral bioavailability and
brain penetration.
"We are extremely pleased that our abstract
was selected for presentation, as this is foundational research that will
inform the selection of a potential future development candidate. The
Neuropsychiatric Drug Development Summit is a unique opportunity to engage with
innovators in neuropsychiatry and to share ideas that ultimately drive the
field forward," said Doug Drysdale, Chief Executive Officer of Cybin.
According to Medtech Pulse last year, “The
major pharmaceutical companies have largely stayed out of the psychedelics
market. The most active player among them is Otsuka with its investments in
Compass Pathways (NASDAQ:CMPS) and Mindset
Pharma (OTC: MSSTF).”
In August, Mindset Pharma, a drug discovery company
developing novel, optimized, next-generation psychedelic and non-psychedelic
medications to treat neuropsychiatric and neurological disorders with unmet
medical needs, announced that they have
entered into a definitive arrangement agreement (the "Agreement")
pursuant to which Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), through
its wholly-owned subsidiary Otsuka America, Inc. ("OAI") will acquire
all of the outstanding shares of Mindset by way of a statutory plan of
arrangement for approximately CAD $80 million in an all-cash transaction (the
"Transaction").
Continued from Medtech Pulse: “Experts expect big pharma companies to step in as soon as the startups
are closer to approval.”
Reporting on the Mindset Pharma (OTC: MSSTF) deal, Psychedelicspotlight.com said, “Big Pharma has certainly taken note of the potential therapeutic
benefits of psychedelics. Otsuka, a major Japanese Pharmaceutical company,
recently signed an agreement to acquire Canada's Mindset Pharma, which
specializes in developing psychedelic medications for neuropsychiatric
disorders.”
“The move is reflective of the growing body of
scientific evidence that indicates psychedelics may hold promise in areas such
as addiction, depression, and anxiety.”
As ResearchNester pointed out
recently, “The increasing investment from venture capitalists and the rising
number of patent filings for psychedelics-related drugs are expected to further
boost the market growth in the upcoming years. Additionally, the increasing
number of collaborations between academic institutes and pharmaceutical
companies are expected to drive the market growth.”
As big Pharma chases the long term opportunity,
investors can watch the small innovators like Kaya Holdings, Inc. (OTCQB: KAYS) pave the way
with alternative health treatments that can be used by patients in treatment
centers today!
Investors following psilocybin and health and
wellness stocks stocks can use the free stock directory at Investor Ideas
https://www.investorideas.com/LOHAS-investing/Stock_List.asp
About
Investorideas.com - Big Investing Ideas
Investorideas.com is a platform for
investing ideas. We publish
breaking stock news, stock research, guest posts and create original top rated
investing podcasts, plus sector tag articles featuring up and coming companies
and industry leaders. Investor Idea’s
original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
We also create
free investor stock directories for AI and tech, biotech, cannabis, cleantech,
crypto, defense, gaming, health and wellness, mining, oil and gas, sports and
water.
Public companies within the sectors we
cover can use our news publishing and content creation services to help tell
their story to interested investors.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Kaya Holdings,
Inc.(OTCQB:KAYS) is a paid featured monthly stock on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and
our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment